| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The targets of Lysyl-tryptophyl-alpha-lysine are not specifically defined in publicly available literature, but the compound is known to have antibacterial and antiviral effects. As a cationic peptide, it likely targets microbial cell membranes through electrostatic interactions, leading to membrane disruption and cell lysis. The two lysine residues provide cationic charges that facilitate binding to negatively charged bacterial membranes. The central tryptophan residue contributes hydrophobic interactions that enhance membrane penetration. The compound's antibacterial and antiviral activities suggest it may have broad-spectrum antimicrobial potential. Further studies are needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Lysyl-tryptophyl-alpha-lysine demonstrates antibacterial and antiviral activity. The compound has been disclosed in patent CN 104072579 A as compound AMP12 with antimicrobial effects. As a cationic tripeptide with two lysine residues and a central tryptophan, the compound likely exhibits membrane-disrupting activity against bacteria and viruses. The antibacterial activity can be evaluated using standard broth microdilution methods to determine minimum inhibitory concentrations (MICs) against various bacterial strains. Antiviral activity can be assessed using cell-based viral replication assays. Detailed in vitro activity data are available from the patent literature.
|
| ln Vivo |
In vivo, Lysyl-tryptophyl-alpha-lysine has not been extensively characterized in publicly available literature. The compound is a small peptide with potential antimicrobial applications. The in vivo efficacy and safety would need to be evaluated in animal models of bacterial or viral infection. The compound's stability in biological fluids and its pharmacokinetic properties would be important considerations for in vivo applications. Further studies are needed to fully characterize its in vivo activity. The compound is for research use only.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies for Lysyl-tryptophyl-alpha-lysine are not specifically described in publicly available literature. As a cationic peptide, its mechanism of action is likely related to membrane disruption rather than specific enzyme or receptor binding. The compound's interactions with microbial membranes could be studied using biophysical techniques such as circular dichroism, fluorescence spectroscopy, or surface plasmon resonance. The peptide's ability to disrupt membrane integrity can be assessed using dye leakage assays or membrane depolarization measurements. These methods are for research purposes only.
|
| Cell Assay |
In vitro cell-based assays for Lysyl-tryptophyl-alpha-lysine evaluate its antimicrobial activity. Bacterial strains (e.g., Gram-positive and Gram-negative bacteria) are cultured in appropriate media and treated with serial two-fold dilutions of the peptide. Minimum inhibitory concentrations (MICs) are determined after 18-24 hours of incubation at 37°C. Time-kill curve assays can be performed to evaluate bactericidal activity over time. Antiviral activity can be assessed using cell lines infected with viruses, measuring viral titers or cytopathic effects. Cytotoxicity assays (MTT or CCK-8) are performed on mammalian cell lines to evaluate selectivity. Standard cell culture and microbiology techniques are used.
|
| Animal Protocol |
In vivo animal studies for Lysyl-tryptophyl-alpha-lysine are not extensively described in publicly available literature. Potential studies could include mouse models of bacterial or viral infection. The peptide would be administered via intraperitoneal, intravenous, or oral routes at various doses. Efficacy would be assessed by measuring pathogen load, survival, and clinical signs. Pharmacokinetic studies would evaluate absorption, distribution, metabolism, and excretion. Toxicology studies would assess safety and tolerability. All procedures must comply with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Lysyl-tryptophyl-alpha-lysine are not characterized in publicly available literature. The compound is a small peptide with a molecular weight of 460.57 g/mol. As a peptide, it may be susceptible to proteolytic degradation in biological fluids. The compound's stability, half-life, and bioavailability would need to be determined in preclinical studies. The compound is for research use only and is not approved for clinical use. Further studies are needed to fully characterize its pharmacokinetic properties.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Lysyl-tryptophyl-alpha-lysine is not fully characterized in publicly available literature. The compound is classified for research use only and not for human consumption. Standard safety precautions for handling peptides apply, including the use of personal protective equipment and working in a chemical fume hood. Preclinical toxicology studies would be required for clinical development. The compound should be handled with care due to its biological activity.
|
| Additional Infomation |
Lys-Trp-Lys is an oligopeptide.
Additional information: Lysyl-tryptophyl-alpha-lysine has the CAS number 38579-27-0 and the molecular formula C₂₃H₃₆N₆O₄. The compound is also known as H-Lys-Trp-Lys-OH and (2S)-6-Amino-2-[[(2S)-2-[[(2S)-2,6-Diamino-1-Oxohexyl]Amino]-3-(1H-Indol-3-Yl)-1-Oxopropyl]Amino]Hexanoic Acid. It is a linear tripeptide consisting of two lysine residues flanking a central tryptophan. The compound has been disclosed in patent CN 104072579 A as compound AMP12 with antibacterial and antiviral effects. The purity is >98% and storage is at -20°C. This product is for research use only and is not approved for clinical or therapeutic applications. |
| Molecular Formula |
C23H36N6O4.C2H4O2
|
|---|---|
| Molecular Weight |
520.6217
|
| Exact Mass |
460.28
|
| CAS # |
38579-27-0
|
| PubChem CID |
161970
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.251g/cm3
|
| Boiling Point |
931.6ºC at 760 mmHg
|
| Flash Point |
517.2ºC
|
| LogP |
3.232
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
33
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
NCCCC[C@@H](C(O)=O)NC([C@H](CC1=CNC2=CC=CC=C12)NC([C@H](CCCCN)N)=O)=O
|
| InChi Key |
YUTZYVTZDVZBJJ-IHPCNDPISA-N
|
| InChi Code |
InChI=1S/C23H36N6O4/c24-11-5-3-8-17(26)21(30)29-20(13-15-14-27-18-9-2-1-7-16(15)18)22(31)28-19(23(32)33)10-4-6-12-25/h1-2,7,9,14,17,19-20,27H,3-6,8,10-13,24-26H2,(H,28,31)(H,29,30)(H,32,33)/t17-,19-,20-/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~217.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9208 mL | 9.6039 mL | 19.2079 mL | |
| 5 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL | |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
